Cornerstone Advisory’s Rigel Pharmaceuticals RIGL Stock Holding History

Cornerstone Advisory’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5	Closed	–	–	656
2021 Q4	$0	Buy	+5	New	+$151	﹤0.01%	832

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cornerstone Advisory's RIGL Position: Q1 2022 in Review

Cornerstone Advisory sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 5 shares.

Cornerstone Advisory first reported a position in RIGL in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

Cornerstone Advisory reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Cornerstone Advisory sold 5 Rigel Pharmaceuticals shares in Q1 2022.
Cornerstone Advisory first reported a position in Rigel Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Cornerstone Advisory's Rigel Pharmaceuticals position peaked at $0 in Q4 2021.
163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.